Sorrento Therapeutics Inc Stock Other OTC
Equities
US83587F1030
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
Mar. 12 | News Highlights : Top Company News of the Day - Tuesday at 5 AM ET | DJ |
Financials (USD)
Sales 2021 | 52.9M | Sales 2022 | 62.84M | Capitalization | 411M |
---|---|---|---|---|---|
Net income 2021 | -428M | Net income 2022 | -573M | EV / Sales 2021 | 29.1 x |
Net Debt 2021 | 111M | Net Debt 2022 | 84.53M | EV / Sales 2022 | 7.89 x |
P/E ratio 2021 |
-3.2
x | P/E ratio 2022 |
-0.65
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.77% |
Managers | Title | Age | Since |
---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 59 | 88-12-31 |
Shawn Sahebi
COO | Chief Operating Officer | - | - |
Mike A. Royal
CTO | Chief Tech/Sci/R&D Officer | 70 | 14-03-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kim D. Janda
BRD | Director/Board Member | 67 | 12-03-31 |
David Lemus
BRD | Director/Board Member | 61 | 17-09-30 |
Jaisim Shah
BRD | Director/Board Member | 63 | 13-09-10 |
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |